Antiretroviral Guidelines
US DHHS Guidelines with Australian commentary
Characteristics of CD4 Post-Attachment Inhibitor
Last Updated: October 25, 2018; Last Reviewed: October 25, 2018
Generic Name (Abbreviation) Trade Name |
Formulation | Dosing Recommendations | Serum Half-Life | Elimination/ Metabolic Pathway | Adverse Events |
---|---|---|---|---|---|
Ibalizumab (IBA) Trogarzo |
Trogarzo:
|
Trogarzo:
|
~64 hours | Not well defined. |
|
Key to Acronyms: IBA = ibalizumab; IV = intravenous |